Skip to main content

First-in-class targeted treatment

TAVNEOS is the only targeted therapy for AAV (GPA/
MPA) to address a key driver of vascular
inflammation in the alternative complement pathway1,2


TAVNEOS reduces the pro-inflammatory effects of C5a, including:1

  • Neutrophil activation and migration
  • Adherence to sites of small blood vessel inflammation
  • Vascular endothelial cell retraction and permeability

TAVNEOS does not block the production of C5b, which is essential for the formation of the membrane attack complex (MAC)1


Activation of the alternative complement pathway plays a key role in AAV, and no established therapies address this key driver of vascular in ammation1,3–8

Already recommended by EULAR 2022

The EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update, recognised the ability of a TAVNEOS-based regimen to improve disease control, and the potential to lower GC toxicity and improve renal function9,10



TAVNEOS (avacopan) in combination with RTX or CYC may be considered for induction of remission in GPA or MPA, as part of a strategy to substantially reduce exposure to GCs1


Consider TAVNEOS in subgroups likely to have enhanced benefit vs GC therapy:9

  • patients at risk of development or worsening of GC-related adverse effects and complications
  • patients with active glomerulonephritis and rapidly deteriorating kidney function

No data on the use of TAVNEOS beyond 1 year, so longer-term use cannot be recommended9


In ADVOCATE, remission was sustained to Week 52 (primary endpoint) at a higher rate in the TAVNEOS-based regimen (65.7%) vs GC-based regimen (54.9%) so TAVNEOS appears to have efficacy for aintenance of remission 9

Reducing relapses

Please rotate your device

Understand more about the pathogenesis of AAV and how TAVNEOS works

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; C5a, complement component 5a; C5aR, C5a receptor; C5b, complement component 5b; C5L2, C5a receptor-like 2; EULAR, European Alliance of Associations for Rheumatology; GC, glucocorticoid; GPA, granulomatosis with polyangiitis; MAC, membrane attack complex; MOA, mechanism of action; MPA, microscopic polyangiitis.

1. Bekker P, et al. PLoS ONE 2016;11(10):e0164646. 2. Thurman JM, Holers VM. J Immunol 2006;176(3):1305–10. 3. Hutton HL, et al. Semin Nephrol 2017;37(5):418–3. 4. Jennette JC, Nachman PH. Clin J Am Soc Nephrol 2017;12(10):1680–91.5. Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34. 6. Lamprecht P, et al. EMJ Rheumatol 2021;8(1):36–42. 7. Liberman AC, et al. Front Endocrinol (Lausanne) 2018;9:235. 8. Nozaki Y. Front Immunol 2021;12:631055. 9. Hellmich B, et al. Ann Rheum Dis 2023;0:1–18. 10. Jayne D, et al. N Eng J Med 2021; 384(7):599–609.